Please login to the form below

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma. ... now with a new immunotherapy and tyrosine kinase inhibitor regimen,” said Dana Walker, vice president, development programme

Latest news

Lilly reports positive data from its phase 3 ulcerative colitis trial

The IL-23 inhibitor also met all key secondary endpoints compared to placebo at week 12, including reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic ... Mirikizumab also reduced
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... Following this initial screening stage, the analysis produced a ranked list of candidates, which included several anti-inflammatory drugs in the Januse kinase (JAK
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
AZ forecasts growth in 2021 after revenues surge in Q4

In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib). ... AZ also reported significant sales growth for checkpoint inhibitor Imfinzi (durvalumab) and PARP
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

The updated results come from the phase 3 CheckMate-9ER trial, which compared BMS’ checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ tyrosine kinase inhibitor (TKI) Cabometyx to Pfizer’s older drug Sutent ... Both Opdivo combinations will

More from news
Approximately 0 fully matching, plus 180 partially matching documents found.

Latest Intelligence

AI: the smart money is on the smart thinking

Using machine learning, a small team of four researchers were able to identify an initial 370 kinase inhibitors, and then quickly narrow this down to the six most likely to work – ... Using GENTRL, the company was able to design a novel DDR1 kinase
Can protein degraders unlock ‘undruggable’ drug targets?

Some groups are focusing on SNIPERs – an acronym for Specific and Non-genetic Inhibitor of apoptosis protein-dependent Protein Erasers. – ... These compounds could be used to tackle resistance to kinase inhibitor drugs, for example.
Deal Watch January 2018

The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9
Deal Watch September 2016

No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
Deal Watch June 2016

acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

Akinion appoints Dr Richard Jones as CEO

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
Creabilis names Catherine Moukheibir as chairman of the board

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Editor: Competitive Salary

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Account Manager: Competitive Salary

Associate Account Director: Competitive Salary

Senior Medical Writer: Competitive Salary

Senior Account Executive: Competitive Salary

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

No results were found

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Empowering patients empowers results: Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials: What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training: Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...